Browsing by Author "Kramberger, M.G. (36544238400)"
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication A European Academy of Neurology guideline on medical management issues in dementia(2020) ;Frederiksen, K.S. (39261216900) ;Cooper, C. (10243664700) ;Frisoni, G.B. (56214208300) ;Frölich, L. (56820309600) ;Georges, J. (7102484391) ;Kramberger, M.G. (36544238400) ;Nilsson, C. (35227764300) ;Passmore, P. (57223659850) ;Mantoan Ritter, L. (8291872500) ;Religa, D. (6603442707) ;Schmidt, R. (57212615213) ;Stefanova, E. (7004567022) ;Verdelho, A. (6602902026) ;Vandenbulcke, M. (56998955200) ;Winblad, B. (36048831500)Waldemar, G. (7006374342)Background and purpose: Dementia is one of the most common disorders and is associated with increased morbidity, mortality and decreased quality of life. The present guideline addresses important medical management issues including systematic medical follow-up, vascular risk factors in dementia, pain in dementia, use of antipsychotics in dementia and epilepsy in dementia. Methods: A systematic review of the literature was carried out. Based on the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework, we developed a guideline. Where recommendations based on GRADE were not possible, a good practice statement was formulated. Results: Systematic management of vascular risk factors should be performed in patients with mild to moderate dementia as prevention of cerebrovascular pathology may impact on the progression of dementia (Good Practice statement). Individuals with dementia (without previous stroke) and atrial fibrillation should be treated with anticoagulants (weak recommendation). Discontinuation of opioids should be considered in certain individuals with dementia (e.g. for whom there are no signs or symptoms of pain or no clear indication, or suspicion of side effects; Good Practice statement). Behavioral symptoms in persons with dementia should not be treated with mild analgesics (weak recommendation). In all patients with dementia treated with opioids, assessment of the individual risk–benefit ratio should be performed at regular intervals. Regular, preplanned medical follow-up should be offered to all patients with dementia. The setting will depend on the organization of local health services and should, as a minimum, include general practitioners with easy access to dementia specialists (Good Practice statement). Individuals with dementia and agitation and/or aggression should be treated with atypical antipsychotics only after all non-pharmacological measures have been proven to be without benefit or in the case of severe self-harm or harm to others (weak recommendation). Antipsychotics should be discontinued after cessation of behavioral disturbances and in patients in whom there are side effects (Good Practice statement). For treatment of epilepsy in individuals with dementia, newer anticonvulsants should be considered as first-line therapy (Good Practice statement). Conclusion: This GRADE-based guideline offers recommendations on several important medical issues in patients with dementia, and thus adds important guidance for clinicians. For some issues, very little or no evidence was identified, highlighting the importance of further studies within these areas. © 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology - Some of the metrics are blocked by yourconsent settings
Publication A European Academy of Neurology guideline on medical management issues in dementia(2020) ;Frederiksen, K.S. (39261216900) ;Cooper, C. (10243664700) ;Frisoni, G.B. (56214208300) ;Frölich, L. (56820309600) ;Georges, J. (7102484391) ;Kramberger, M.G. (36544238400) ;Nilsson, C. (35227764300) ;Passmore, P. (57223659850) ;Mantoan Ritter, L. (8291872500) ;Religa, D. (6603442707) ;Schmidt, R. (57212615213) ;Stefanova, E. (7004567022) ;Verdelho, A. (6602902026) ;Vandenbulcke, M. (56998955200) ;Winblad, B. (36048831500)Waldemar, G. (7006374342)Background and purpose: Dementia is one of the most common disorders and is associated with increased morbidity, mortality and decreased quality of life. The present guideline addresses important medical management issues including systematic medical follow-up, vascular risk factors in dementia, pain in dementia, use of antipsychotics in dementia and epilepsy in dementia. Methods: A systematic review of the literature was carried out. Based on the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework, we developed a guideline. Where recommendations based on GRADE were not possible, a good practice statement was formulated. Results: Systematic management of vascular risk factors should be performed in patients with mild to moderate dementia as prevention of cerebrovascular pathology may impact on the progression of dementia (Good Practice statement). Individuals with dementia (without previous stroke) and atrial fibrillation should be treated with anticoagulants (weak recommendation). Discontinuation of opioids should be considered in certain individuals with dementia (e.g. for whom there are no signs or symptoms of pain or no clear indication, or suspicion of side effects; Good Practice statement). Behavioral symptoms in persons with dementia should not be treated with mild analgesics (weak recommendation). In all patients with dementia treated with opioids, assessment of the individual risk–benefit ratio should be performed at regular intervals. Regular, preplanned medical follow-up should be offered to all patients with dementia. The setting will depend on the organization of local health services and should, as a minimum, include general practitioners with easy access to dementia specialists (Good Practice statement). Individuals with dementia and agitation and/or aggression should be treated with atypical antipsychotics only after all non-pharmacological measures have been proven to be without benefit or in the case of severe self-harm or harm to others (weak recommendation). Antipsychotics should be discontinued after cessation of behavioral disturbances and in patients in whom there are side effects (Good Practice statement). For treatment of epilepsy in individuals with dementia, newer anticonvulsants should be considered as first-line therapy (Good Practice statement). Conclusion: This GRADE-based guideline offers recommendations on several important medical issues in patients with dementia, and thus adds important guidance for clinicians. For some issues, very little or no evidence was identified, highlighting the importance of further studies within these areas. © 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology - Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators(2024) ;Jessen, Frank (7006672877) ;Kramberger, M.G. (36544238400) ;Angioni, D. (57218317683) ;Aarsland, D. (56222844000) ;Balasa, M. (36668211900) ;Bennys, K. (6507192782) ;Boada, M. (57192408353) ;Boban, M. (56186239100) ;Chincarini, A. (55885268100) ;Exalto, L. (26658986600) ;Felbecker, A. (35746236900) ;Fliessbach, K. (6506812066) ;Frisoni, G.B. (56214208300) ;Garza-Martínez, A.J. (57394406400) ;Grimmer, T. (6507487659) ;Hanseeuw, B. (35114773100) ;Hort, J. (15020481600) ;Ivanoiu, A. (57219106513) ;Klöppel, S. (23100462800) ;Krajcovicova, L. (24724610700) ;McGuinness, B. (57192408447) ;Mecocci, P. (7006313835) ;de Mendonca, A. (55307490700) ;Nous, A. (57216750798) ;Ousset, P.-J. (7003951573) ;Paquet, C. (23502231800) ;Perneczky, R. (57209088266) ;Peters, O. (57204202580) ;Tabuas-Pereira, M. (56493155900) ;Piazza, F. (57863283300) ;Plantone, D. (26538821100) ;Riverol, M. (24462200800) ;Ruiz, A. (7203006899) ;Sacco, G. (55556226500) ;Santana, I. (6603922366) ;Scarmeas, N. (6701754861) ;Solje, E. (56232842500) ;Stefanova, E. (7004567022) ;Sutovsky, S. (22952529500) ;van der Flier, W. (8548678900) ;Welsh, T. (55820604800) ;Wimo, A. (56235097300) ;Winblad, B. (36048831500) ;Frölich, L. (56820309600)Engelborghs, S. (7004850774)β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer’s Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current β-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases. © The Authors 2024.
